Provided by Tiger Trade Technology Pte. Ltd.

Halozyme Therapeutics

108.29
-2.5050-2.26%
Volume:278.71K
Turnover:30.34M
Market Cap:12.29B
PE:32.02
High:110.00
Open:109.30
Low:108.14
Close:110.79
52wk High:116.85
52wk Low:61.23
Shares:113.50M
Float Shares:112.00M
Volume Ratio:0.62
T/O Rate:0.25%
Dividend:- -
Dividend Rate:- -
EPS(TTM):3.38
EPS(LYR):2.56
ROE:173.67%
ROA:25.49%
PB:85.62
PE(LYR):42.30

Loading ...

Halozyme Therapeutics, Inc. : H.c. Wainwright Raises Target Price to $130 from $115

THOMSON REUTERS
·
2 hours ago

U.S. Research Roundup-BlackRock, Evercore, Goldman Sachs

Reuters
·
6 hours ago

Does Patent Injunction Win Change The Bull Case For Halozyme Therapeutics (HALO)?

Simply Wall St.
·
20 hours ago

US Stocks on the MOVE-Halozyme, Moderna, Merck

Reuters
·
20 hours ago

Sector Update: Healthcare

MT Newswires Live
·
21 hours ago

Merck's Keytruda is Dealt a Legal Setback. It's Good News for This Biotech Stock.

Dow Jones
·
22 hours ago

U.S. Stocks on the MOVE-Halozyme, BKV, AppFolio

Reuters
·
22 hours ago

Halozyme Therapeutics Shares up 2% After Court Win Against Merck to Block Subcutaneous Keytruda in Select Markets

THOMSON REUTERS
·
Yesterday

Halozyme announces Dutch court of the Hague found Merck infringed patents

TIPRANKS
·
Yesterday

Halozyme Wins Dutch Court Injunction Blocking Merck Keytruda SC in Eight European Markets over EP622 Patent

Reuters
·
Yesterday

Halozyme Therapeutics - Iv Version of Keytruda Remains Available and not Covered by Halozyme's Patent or Court Injunction

THOMSON REUTERS
·
Yesterday

Halozyme Therapeutics - Court Rejects Merck's Arguments That Ep622 Patent is Invalid

THOMSON REUTERS
·
Yesterday

Halozyme Wins Injunction Stopping Manufacture and Sale of Merck's Keytruda Sc in Multiple European Markets

THOMSON REUTERS
·
Yesterday

Halozyme Therapeutics - Court Orders Msd BV to Stop Keytruda Sc Manufacture and Sale in Eight European Countries

THOMSON REUTERS
·
Yesterday

Halozyme Therapeutics - Injunction Forbids Msd from Facilitating Infringement by Affiliates

THOMSON REUTERS
·
Yesterday

Halozyme Expands Enhanze Collaboration with Argenx to Cover Two Additional Exclusive Targets

Reuters
·
Yesterday

Halozyme Therapeutics - Eligible for Milestone Payments and Royalties on Enhanze Product Sales

THOMSON REUTERS
·
Yesterday

Halozyme Announces Expansion of Global Collaboration and License Agreement with Argenx to Support the Development of Subcutaneous Formulations for Two Additional Exclusive Targets Using Its Enhanze® Technology

THOMSON REUTERS
·
Yesterday

Halozyme Therapeutics - Increases Argenx's Exclusive Access to Enhanze Increased from Six to Eight Targets

THOMSON REUTERS
·
Yesterday

Halozyme Therapeutics (HALO) Adds Jim Daly As Valuation Questions Follow

Simply Wall St.
·
Oct 04